Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain...(000-fold ormore actual studies with warm...),Health

Date:9/10/2008

000-fold or more, actual studies with warm-blood mammals showed over-activation of the Sirtuin1 gene increases the occurrence of heart failure by more than 7.5 fold. [Sirt1 regulates aging and resistance to oxidative stress in the heart. Circulation Research 2007; 100: 1512-21]

-- While it was initially believed only mega-dose resveratrol would be effective, and that strong Sirtuin1 gene activators would be required, a much lower dose of resveratrol (100 milligrams human equivalent of trans resveratrol, 4 to 320 times lower than previous studies, when provided in a patent-applied for matrix of other small molecules), exerted a 9-fold greater genomic effect than plain resveratrol or a calorie-restricted diet. In this study, calorie restriction significantly differentiated (up or down-regulated) 198 genes, and resveratrol, its molecular mimic, significantly influenced 225 genes, while resveratrol-based matrix (Longevinex(R)) significantly differentiated 1711 genes. [Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Experimental Gerontology 2008 Sep;43(9):859-66]

Sardi says websites selling resveratrol supplements still parrot earlier but now outdated news reports about Sirtuin1 genes and mega-doses appear oblivious to the striking changes in resveratrol science that have been recently published. "Paying heed to the current data now available, mega-dose resveratrol is ill-advised and may be related to uncommon but reported side effects, namely Achilles heel tendon inflammation, skin rash, joint stiffening, flu-like symptoms and numbness in fingertips, all which are reversible," says Sardi.

Some marketers of resveratrol supplements still misguidedly refer to the 2006 study published in Nature Magazine where mice lived longer on a resveratrol-fed diet, but these mice were fed a 60% fat-calorie diet which could not possibly be achieved by humans. (Humans con
'/>"/>

SOURCE Resveratrol Partners, LLC Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
2. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
6. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
7. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
8. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
9. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
10. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer